Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
about
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularEpidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaPharmGKB summary: very important pharmacogene information for the epidermal growth factor receptorIncreased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer.Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Management of patients with advanced non-small cell lung cancer: role of gefitinibEpidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene MutationA new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularPooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCDifferent efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysisFool's gold, lost treasures, and the randomized clinical trial.Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.Gefitinib in non small cell lung cancerThe emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutationsGenotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesThe Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary DiseasesBiomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASQuality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapyAn Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersMolecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statementStructure and clinical relevance of the epidermal growth factor receptor in human cancerDetection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clampingLung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Somatic pharmacogenomics in cancer.Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Gefitinib for the treatment of non-small-cell lung cancer.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Gefitinib for the treatment of non-small-cell lung cancer.
P2860
Q26797297-0B564A6E-B32C-420F-9C35-01C2B4567069Q26828860-F80535FF-6159-46CC-AA13-7D66A6FD9C25Q28284519-C0A3F0DE-7E01-48E6-A929-B776FD74B5B6Q28303718-564D2A95-4C2C-4085-84CC-D88B6CD97569Q28382921-4748C4BD-9B57-4C94-A48E-DF316B068844Q30279226-26198EC2-52C3-444A-B91E-2BAEADE47565Q33857652-B309915F-48A4-49F8-9142-F45ADF62AD22Q33892582-6419AF36-E0DB-485A-8759-AE69F9AE5FE2Q33892597-6EBE9025-DCDA-49A8-AF7E-D9D4016BF453Q34031229-B0279912-6FF7-4808-B4C2-7521B6641217Q34059536-19881463-3DF3-4EFA-93F2-F72FD5397783Q34141560-2CC9F9E8-6630-4A68-AC98-F11140A946F2Q34159011-C9A7CBD8-1210-4119-85F7-7CF0AED8BC30Q34311186-CB90E1EF-37C2-42F0-BB67-8C1590EDEE41Q34333839-FAF1FD59-DBB6-40BF-9BB9-49CFA3501A95Q34669260-EE05F1C5-1329-4374-801E-9527F183A8D7Q35013457-0279AD44-C9D8-4A43-9DF5-5DC6F1069110Q35031807-F1396473-07FB-476D-88B0-C0D37A1633E6Q35076292-5FB86313-DE04-4240-9814-3209621B20DAQ35146927-A9E3F653-955F-4E30-8556-C6882529632AQ35608617-58753E8A-2A95-4305-BD81-8AA9651A0C09Q36040606-29F9A486-E532-4505-831F-8AA3E6BED627Q36051542-BCA3F7B0-FC96-435D-9F64-3426988DD9B8Q36095650-79E02B48-A34A-494F-A8CA-B6513C594198Q36135844-DCCDAE91-E892-44A2-BDBB-125CC45D7903Q36228469-DC497730-D1D7-4747-859A-5CB3A2425944Q36817080-A5019A80-8136-412A-9DA8-0535DC79B3AEQ36905639-1F50AFBE-8E6D-456C-947A-BAB58F2026A7Q36929734-9A558B9F-4C2D-41AB-9572-F09D9EE38449Q37102068-19FB30D4-8741-4973-BC9F-8F6720CF371FQ37122918-4E871742-5742-43DF-885B-4BF4553252A8Q37141952-0DE68D21-0EF9-4CCE-B2D5-22AF547CC92EQ37147755-20941C56-140E-46C7-8FB7-33B1A3E1B82AQ37235024-74F676B6-2E64-4676-89B7-D34E3575098EQ37307603-7F522C57-ECFD-4D5E-9268-E8CAAAEECF6EQ37334996-F0BE5FAC-6E7A-4231-9CCF-CC466D8A0432Q37357287-EE962E72-7931-4290-A989-2FE761CE5718Q37379113-45CA3EEF-5D10-4208-8B99-A617BCDE5E5BQ37637905-5E33BEB6-501D-4AC2-BECC-9937E58D8EEDQ37738913-56AEB7EE-7DB9-43D5-B482-0170F817A145
P2860
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@ast
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@en
type
label
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@ast
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@en
prefLabel
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@ast
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@en
P2093
P2860
P356
P1476
Gefitinib for non-small-cell l ...... -locked nucleic acid PCR clamp
@en
P2093
H Miyazawa
K Hagiwara
K Kobayashi
M Kanazawa
Y Murayama
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603466
P407
P577
2006-11-14T00:00:00Z